1st Counsel – Lifestyle
Author:
Aptevo Therapeutics
Aptevo Provides State of the Business Report and 2025 Financial Results
March 26, 2026
Aptevo to Participate in March 2026 Conferences
March 19, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
March 10, 2026